4D pharma plc (LBPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
LBPS Stock Price Chart Interactive Chart >
LBPS Price/Volume Stats
|Current price||$1.65||52-week high||$11.09|
|Prev. close||$1.61||52-week low||$1.50|
|Day high||$1.65||Avg. volume||221,212|
|50-day MA||$3.31||Dividend yield||N/A|
|200-day MA||$5.04||Market Cap||27.11M|
4D pharma plc (LBPS) Company Bio
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.
Most Popular Stories View All
LBPS Latest News Stream
|Loading, please wait...|
LBPS Latest Social Stream
View Full LBPS Social Stream
Latest LBPS News From Around the Web
Below are the latest news stories about 4D PHARMA PLC that investors may wish to consider to help them evaluate LBPS as an investment opportunity.
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Baudax Bio (BXRX) and 4d Pharma (LBPS)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Onconova Therapeutics (ONTX – Research Report), Baudax Bio (BXRX – Research Report) and 4d Pharma (LBPS – Research Report) with bullish sentiments. Onconova Therapeutics (ONTX) In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Onconova Therapeutics, with a price target of $11.00. The company's shares closed last Friday at $1.85, close to its 52-week low of $1.38. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 5.4% and a 32.9% success rate.
Good morning, investor!
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
LEEDS, England, March 31, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
LBPS Price Returns